CAJ | 학술논문

目的探讨口服罗红霉素对慢性阻塞性肺疾病(COPD)患者肺功能的影响,并分析其可能的机制.方法将50例COPD患者采用随机、单盲方法分成治疗组25例与对照组25例,其中对照组采用常规基础治疗,治疗组在常规基础治疗基础上口服罗红霉素0.15 g,2次/d,并持续1年.观察两组患者治疗前后外周血中性粒细胞计数及肺功能的变化,统计分析两组患者发生病情急性加重及因此而需住院的次数.结果治疗组患者治疗前后外周血中性粒细胞计数差异有统计学意义(P<0.05);治疗组第1秒用力呼气容积占用力肺活量百分比(FEV_1/FVC)、第1秒用力呼气容积占预计值百分比(FEV1%预计值)、最大通气量、清晨最大呼气流量治疗前后改变不明显(P>0.05),对照组却有明显下降(P<0.05),两组患者治疗前后肺功能的变化差异有统计学意义(P<0.05);治疗组急性加重10例次(4J0%),对照组19例次(76%);治疗组需住院6例次(24%),对照组13例次(52%),两组急性加重率及需住院率比较差异均有统计学意义(P<0.05).结论口服罗红霉素对COPD患者肺功能具有保护作用,其可能的机制与罗红霉素对中性粒细胞的抑制作用有关.
목적 탐토구복라홍매소대만성조새성폐질병(COPD)환자폐공능적영향,병분석기가능적궤제.방법 장50례COPD환자채용수궤、단맹방법 분성치료조25례여대조조25례,기중대조조채용상규기출치료,치료조재상규기출치료기출상구복라홍매소0.15 g,2차/d,병지속1년.관찰량조환자치료전후외주혈중성립세포계수급폐공능적변화,통계분석량조환자발생병정급성가중급인차이수주원적차수.결과 치료조환자치료전후외주혈중성립세포계수차이유통계학의의(P<0.05);치료조제1초용력호기용적점용력폐활량백분비(FEV_1/FVC)、제1초용력호기용적점예계치백분비(FEV1%예계치)、최대통기량、청신최대호기류량치료전후개변불명현(P>0.05),대조조각유명현하강(P<0.05),량조환자치료전후폐공능적변화차이유통계학의의(P<0.05);치료조급성가중10례차(4J0%),대조조19례차(76%);치료조수주원6례차(24%),대조조13례차(52%),량조급성가중솔급수주원솔비교차이균유통계학의의(P<0.05).결론 구복라홍매소대COPD환자폐공능구유보호작용,기가능적궤제여라홍매소대중성립세포적억제작용유관.
Objective To evaluate the effect of oral roxithromyein on lung function in chronic obstructive pulmonary disease (COPD) and analyse the probable mechanism. Methods Fifty patients with COPD were divided randomly into treatment group (25 eases) and control group (25 eases). The control group was treated with base therapy, and the treatment group was treated with oral roxithromycin beside base therapy, 0.15 g, twice one day for one year. Then the changes of peripheral blood neutrophil and lung function was observed before and after treatment, and the times of acute exacerbation were statistically analyzed.Results There was significant difference in the changes of peripheral blood neutrophil in treatment group (P<0.05). The ratio of forced expiratory volume in one second and forced vital capacity (FEV_1/FVC),FEV_1% pred, peak expiratory flow, maximal vital volume had no obvious change in treatment group (P>0.05), but had obvious decrease in control group (P<0.05 ). There was significant difference in the changes of lung function in two groups(P<0.05 ). The times of acute exacerbation were 10(40%) in treatment group and 19 (76%) in control group, and the times of need to be in hospital were 6 (24%) and 13 (52%)respectively. There were significant difference (P<0.05). Conclusion Long-term oral roxithromyein can protect the lung function of COPD patients, the probable mechanism is that roxithromyein inhibit the neutrophil's function.